CCNE1 and ovarian serous adenocarcinoma: (Etemadmoghadam et al., 2013) Early clinical data of the combination of checkpoint kinase inhibition and immune checkpoint blockade showed durable responses in several CCNE1 amplified patients with high grade serous ovarian cancers, suggesting an interplay between cell cycle inhibition, DNA damage repair and the immune response.